# Alto Pharmacy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alto-pharmacy

- Industry: Healthcare IT
- Headquarters: San Francisco, US
- Website: www.alto.com
- Total disclosed funding: $335M
- Latest round: Series E (Jan 14, 2022)
- Investors on record: 10

## About

Alto Pharmacy, LLC is a U.S.-based healthcare company specializing in pharmacy services that enhance patient experiences through technology-driven solutions and specialized medication delivery.Founded in 2015 and headquartered in San Francisco, US, Alto Pharmacy, LLC focuses on providing innovative pharmacy services. The company has undergone strategic pivots to emphasize technology in medication management. Jamie Karraker, Lisa Dashiell, and Mattieu Gamache-Asselin are the founders, while Alicia Davis serves as the CEO. Alto has successfully raised USD 120.00 mn through 12 funding rounds, with the latest round occurring recently, achieving a current valuation of USD 800.00 mn.Alto Pharmacy offers a range of pharmacy services designed to improve patient care through technological integration. Their platform features an app for managing prescription orders and payments, providing both same-day delivery and pharmacy pick-up services. Notably, Alto specializes in fertility medications, supporting over 160,000 fertility journeys since 2016, with services available nationwide across all 50 states.The company generates revenue through a transaction model encompassing direct-to-consumer and business-to-business interactions, largely through partnerships with healthcare providers and fertility clinics. Revenue primarily comes from prescription fulfillment services, including the delivery of specialty medications. The Alto app facilitates convenience in ordering medications and may include subscription options for ongoing needs, enhancing their service value.Alto Pharmacy plans to leverage recent funding from GDP Venture to further develop its technology and expand its market presence. The company is focused on launching new product offerings aimed at enhancing customer engagement and improving healthcare access. Specific geographic expansions are targeted, although precise regions and timelines are not disclosed. The funding will support these growth initiatives, enabling Alto to enhance its service capabilities and reach more patients.

## Funding rounds

- Series E, Jan 14, 2022, $132M — Gaingels, SB Investment Advisers
- Series D, Dec 10, 2019, $129M — Greenoaks Capital, Jackson Square Ventures, SB Investment Advisers, LIAN Group, Zola Capital Management, LLC, Olive Tree Capital, Esas Holdings
- Series C, Aug 21, 2018, $50M — Greenoaks Capital, Jackson Square Ventures, Zola Capital Management, LLC, Olive Tree Capital
- Series B, Dec 6, 2017, $17M — Greenoaks Capital, Jackson Square Ventures
- Series A, Jul 25, 2016, $6.6M — Jackson Square Ventures
- Seed, Jun 20, 2015 — Soma Capital Management, Palapa Ventures

## Investors

- Soma Capital Management (https://capitalatlas.ai/funds/soma-capital-management) — Seed
- Palapa Ventures (https://capitalatlas.ai/funds/palapa-ventures) — Seed
- Jackson Square Ventures (https://capitalatlas.ai/funds/jackson-square-ventures) — Series A, Series B, Series C, Series D
- Greenoaks Capital (https://capitalatlas.ai/funds/greenoaks-capital) — Series B, Series C, Series D
- Zola Capital Management, LLC — Series C, Series D
- Olive Tree Capital (https://capitalatlas.ai/funds/olive-tree-capital) — Series C, Series D
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series D, Series E
- LIAN Group (https://capitalatlas.ai/funds/lian-group) — Series D
- Esas Holdings (https://capitalatlas.ai/funds/esas-holdings) — Series D
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series E